Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 10/20 | 0.72 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.72 |
| ▸ | RAF1 | P04049 | 2/20 | 0.71 |
| ▸ | BRAF | P15056 | 1/20 | 0.71 |
| ▸ | KDR | P35968 | 6/20 | 0.71 |
| ▸ | RET | P07949 | 4/20 | 0.71 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.70 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.70 |
| ▸ | EPHB2 | P29323 | 2/20 | 0.69 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.69 |
| ▸ | FLT1 | P17948 | 1/20 | 0.69 |
| ▸ | CDK2 | P24941 | 1/20 | 0.69 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.69 |
| ▸ | KIF5B | P33176 | 1/20 | 0.69 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.69 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.68 |
| ▸ | SRC | P12931 | 4/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.66 |
| ▸ | ABL1 | P00519 | 2/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5485308 | 0.90 | EGFR (0.77) | EGFRMAPK14RAF1KDRRET | |
| Hydrochloric Acid SCHEMBL5471735 | 0.89 | EGFR (0.75) | EGFRMAPK14RAF1KDRRET | |
| SCHEMBL5569469 | 0.87 | KDR (0.72) | EGFRKDRRETABCG2FLT1 | |
| SCHEMBL3238919 | 0.85 | EGFR (0.70) | EGFRMAPK14RAF1KDRRET | |
| Hydrochloric Acid SCHEMBL3238911 | 0.84 | EGFR (0.68) | EGFRMAPK14RAF1KDRRET | |
| SCHEMBL15051752 | 0.84 | BRAF (1.00) | RAF1BRAF | |
| SCHEMBL17940152 | 0.84 | EGFR (0.70) | EGFRMAPK14RAF1BRAFKDR | |
| SCHEMBL6785711 | 0.84 | MAPK14 (1.00) | EGFRMAPK14KDRSRCAURKA | |
| SCHEMBL5569018 | 0.83 | KDR (1.00) | EGFRMAPK14RAF1KDRRET | |
| SCHEMBL6786328 | 0.83 | EGFR (0.77) | EGFRMAPK14RAF1BRAFKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | GPC BIOTECH AG (DE) | 2007-05-31 | — | — | US | claimed |
| EP-1673346-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC Biotech AG (DE) | 2006-06-28 | — | — | EP | claimed |
| WO-2005040125-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC BIOTECH AG (DE) | 2005-05-06 | — | — | WO | claimed |
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | GPC BIOTECH AG (DE) | 2007-05-31 | — | — | US | disclosed |
| EP-1673346-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC Biotech AG (DE) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005040125-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC BIOTECH AG (DE) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | IRF3, PML, TPMT | EGFR 1445/4885MAPK14 423/4885RAF1 983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.